BeyondSpring Reports Compelling New Data: Plinabulin Advances Both the Anticancer Efficacy and Safety of ADC Drugs
Go back to BeyondSpring Reports Compelling New Data: Plinabulin Advances Both the Anticancer Efficacy and Safety of ADC Drugs| (NASDAQ: BYSI) | Delayed: 1.62 +0.01 (0.62%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.61 | 52 Week High | $ | |||
| Open | $1.62 | 52 Week Low | $ | |||
| Day High | $1.65 | P/E | N/A | |||
| Day Low | $1.55 | EPS | $ | |||
| Volume | 8,250 | |||||
